- Home
- PHK vs KURA Comparison
PHK vs KURA Comparison
Compare PHK & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- KURA
- Stock Information
- Founded
- PHK 2003
- KURA 2014
- Country
- PHK United States
- KURA United States
- Employees
- PHK N/A
- KURA N/A
- Industry
- PHK Finance/Investors Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHK Finance
- KURA Health Care
- Exchange
- PHK Nasdaq
- KURA Nasdaq
- Market Cap
- PHK 777.7M
- KURA 793.2M
- IPO Year
- PHK N/A
- KURA N/A
- Fundamental
- Price
- PHK $4.87
- KURA $9.01
- Analyst Decision
- PHK
- KURA Strong Buy
- Analyst Count
- PHK 0
- KURA 10
- Target Price
- PHK N/A
- KURA $30.13
- AVG Volume (30 Days)
- PHK 491.5K
- KURA 2.5M
- Earning Date
- PHK 01-01-0001
- KURA 11-07-2024
- Dividend Yield
- PHK 12.61%
- KURA N/A
- EPS Growth
- PHK N/A
- KURA N/A
- EPS
- PHK N/A
- KURA N/A
- Revenue
- PHK N/A
- KURA N/A
- Revenue This Year
- PHK N/A
- KURA N/A
- Revenue Next Year
- PHK N/A
- KURA $106.66
- P/E Ratio
- PHK N/A
- KURA N/A
- Revenue Growth
- PHK N/A
- KURA N/A
- 52 Week Low
- PHK $4.13
- KURA $8.85
- 52 Week High
- PHK $5.15
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- PHK 30.39
- KURA 22.05
- Support Level
- PHK $4.81
- KURA $8.85
- Resistance Level
- PHK $5.09
- KURA $10.02
- Average True Range (ATR)
- PHK 0.05
- KURA 0.48
- MACD
- PHK -0.02
- KURA 0.08
- Stochastic Oscillator
- PHK 22.14
- KURA 6.30
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.